RT期刊文章SR电子T1放射性示踪剂的作用成像在帕金森病摩根富林明神经学神经学乔FD Lippincott Williams &威尔金斯SP 208 OP 215做10.1212/01首页. wnl.0000149403.14458.7f VO 64 2 A1 b Ravina A1 d Eidelberg A1 j . e . Ahlskog A1 r·l·阿尔宾A1 d·j·布鲁克斯A1 m .碳A1 V。Dhawan A1。费金A1 s Fahn A1 m .格特曼A1 K。Gwinn-Hardy A1 h·麦克法兰A1 r .英尼斯A1 r . g . Katz A1 K。Kieburtz A1 s . j .基士A1 n·兰格A1 j·w·兰斯顿·A1 K。Moy Marek A1 l·莫林A1 c A1 d·墨菲A1 W。h . Oertel A1 g·奥利弗A1 y Palesch A1 W。权力A1 j . Seibyl A1 K。d . Sethi A1 c . w . Shults A1 p Sheehy A1。j . Stoessl A1 r·霍洛韦年2005 UL http://n.neurolog首页y.org/content/64/2/208.abstract AB放射性示踪剂成像(RTI)的黑多巴胺能系统是一个被广泛使用,但在帕金森病(PD)有争议的生物标志物。 Here the authors review the concepts of biomarker development and the evidence to support the use of four radiotracers as biomarkers in PD: [18F]fluorodopa PET, (+)-[11C]dihydrotetrabenazine PET, [123I]β-CIT SPECT, and [18F]fluorodeoxyglucose PET. Biomarkers used to study disease biology and facilitate drug discovery and early human trials rely on evidence that they are measuring relevant biologic processes. The four tracers fulfill this criterion, although they do not measure the number or density of dopaminergic neurons. Biomarkers used as diagnostic tests, prognostic tools, or surrogate endpoints must not only have biologic relevance but also a strong linkage to the clinical outcome of interest. No radiotracers fulfill these criteria, and current evidence does not support the use of imaging as a diagnostic tool in clinical practice or as a surrogate endpoint in clinical trials. Mechanistic information added by RTI to clinical trials may be difficult to interpret because of uncertainty about the interaction between the interventions and the tracer.